Literature DB >> 8593743

The allometric approach for interspecies scaling of pharmacokinetics and toxicity of anti-cancer drugs.

J W Paxton1.   

Abstract

1. The rationale for extrapolation or 'scaling' across animal species is based on their underlying anatomical, physiological and biochemical similarities. 2. Research carried out in the 19th and early 20th century resulted in Benedict's famous 'mouse-to-elephant' graph which showed that the log of the basal metabolic rate plotted against the log of bodyweight (W) produced a straight line with a slope of 0.76. Since then it has become apparent that a number of other physiological variables (Y) exhibit a similar relationship which can be represented by the general allometric equation, Y = alpha W beta; where beta is the slope of the log-log plot and alpha is the intercept on the y axis. 3. The major pharmacokinetic parameters such as clearance and volume of distribution of many drugs are also related to W in a similar manner. 4. This empirical approach does not require a strong mathematical background and offers a relatively simple method of predicting the kinetics of anti-cancer drugs in patients from pre-clinical animal data. 5. The occurrence of major qualitative and quantitative differences in the metabolism of drugs between species is probably the single greatest complicating factor in the use of animals as predictors of drug toxicity and kinetics in patients. 6. Despite this, the allometric approach is useful for allowing the estimation of a more appropriate starting dose for some drugs in a Phase I trial, which might result in potential savings in escalation steps and maximize the chance that the dose which an individual receives has the potential for therapeutic value.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 8593743     DOI: 10.1111/j.1440-1681.1995.tb01949.x

Source DB:  PubMed          Journal:  Clin Exp Pharmacol Physiol        ISSN: 0305-1870            Impact factor:   2.557


  4 in total

Review 1.  Pharmacokinetic-pharmacodynamic guided trial design in oncology.

Authors:  Ch van Kesteren; R A A Mathôt; J H Beijnen; J H M Schellens
Journal:  Invest New Drugs       Date:  2003-05       Impact factor: 3.850

2.  Preclinical pharmacology of novel indolecarboxamide ML-970, an investigative anticancer agent.

Authors:  Elizabeth Rayburn; Wei Wang; Mao Li; Xu Zhang; Hongxia Xu; Haibo Li; Jiang-Jiang Qin; Lee Jia; Joseph Covey; Moses Lee; Ruiwen Zhang
Journal:  Cancer Chemother Pharmacol       Date:  2012-02-25       Impact factor: 3.333

3.  Combination exposure to zidovudine plus sulfamethoxazole-trimethoprim diminishes B-lymphocyte immune responses to Pneumocystis murina infection in healthy mice.

Authors:  David J Feola; Beth A Garvy
Journal:  Clin Vaccine Immunol       Date:  2006-02

4.  Animal models and conserved processes.

Authors:  Ray Greek; Mark J Rice
Journal:  Theor Biol Med Model       Date:  2012-09-10       Impact factor: 2.432

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.